Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Operating Cash Flow: Achieved positive operating cash flow for the first time in Q3 2024. Total Operating Expenses: $103.9 million, including R&D expense of $31.7 million and SG&A expense of $50.5 million. Net Loss: $15 million or $0.32 per share. Cash, Cash Equivalents, and Investments: $293.8 million as of September 30, 2024. Livmarli Global Net Product Sales: $59.1 million, with US sales at $43.5 million and international sales at $15.6 million. Kolbam and Chenodal Net Product Sales: $31.2 million in Q3 2024. Warning! GuruFocus has detected 3 Warning Sign with MIRM. Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Mirum Pharmaceuticals Inc ( NASDAQ:MIRM ) reported a significant increase in net product sales, reaching $90.3 million in Q3 2024, an 89% increase from the same quarter last year. The company has raised its full-year 2024 guidance to $330 to $335 million in net product
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingBusiness Wire
- Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.MarketBeat
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $65.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
MIRM
Earnings
- 11/12/24 - Beat
MIRM
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- MIRM's page on the SEC website